Dupixent Keeps Sanofi At Forefront Of European Pharma Growth
Hints At Raised Forecast For Blockbuster
Sanofi is on a roll thanks to Dupixent and the blockbuster is providing breathing space even when some key pipeline assets are delayed.
You may also be interested in...
The France-headquartered company has brought forward its carbon neutral goal, making it one of the sector’s most proactive companies.
The companies announced positive Phase III data for the drug in patients with eosinophilic esophagitis and plan to take the results to regulators in 2022.
The French major and partner Regeneron expect to file Dupixent for the rare skin disease next year after a Phase III trial of the blockbuster hit its primary and secondary endpoints.